Jamieson Wellness Publishes Inaugural Sustainability Impact Report

From values to action, the Company details progress towards its sustainability commitments in its "Inspiring Better Lives Every Day: 2023 Sustainability Impact Report"

Jamieson Wellness Inc. ("Jamieson Wellness" or the "Company") (TSX: JWEL) today announces the release of its "Inspiring Better Lives Every Day: 2023 Sustainability Impact Report". The comprehensive report underscores the Company's commitment to creating a sustainable future while aligning with its core values of Respect, Excellence, Accountability, and Agility. The Company's new purpose, "Inspiring Better Lives Every Day," serves as its guiding light as it navigates the path toward positive impact.

Key Highlights from the 2023 report:

  • Performance Metrics: The report meticulously outlines the Company's performance across various dimensions, including promoting diversity in the workplace, fostering wellbeing within Jamieson Wellness and its communities, and progress towards climate and biodiversity targets
  • ‘Progress For Our People': Jamieson Wellness has embarked on several initiatives aimed at improving the wellbeing of its consumers, team members, and communities, from inclusion and equitable workplace training, to protecting human rights and supporting community giving programs
  • ‘Progress For Our Planet': Transparent insights into the Company's progress toward achieving ambitious sustainability goals, including a new environmental policy, as well as the introduction of Ocean-Friendly Omega, the youtheory brand's award-winning plant-based omega-3 product
  • ESG Scorecard: As part of the Company's commitment to its value of Accountability, the report presents its Environmental, Social, and Governance (ESG) Scorecard. This includes adherence to the new International Sustainability Standards Board's global standards, incorporating the Task Force on Climate-Related Financial Disclosures recommendations, and reporting its Sustainability Accounting Standards Board metrics
  • Greenhouse Gas Inventory Assurance Report: The Company's greenhouse gas emissions inventory is disclosed in this report for the first time. It undergoes rigorous assurance processes and will be reported annually as part of the Company's dedication to reaching Net Zero by 2050

"We are immensely proud of the progress we have made in our ESG initiatives, and of the dedicated work that went into creating this comprehensive report," said Mike Pilato, President and CEO of Jamieson Wellness. "This report not only reflects our unwavering commitment to a healthier world, but it also resonates deeply with our company purpose: "Inspiring Better Lives Every Day". As we continue to lead with purpose, innovate, and drive positive change, we invite our stakeholders to join us on this transformative journey."

The full report can be found on the Company's website here .

About Jamieson Wellness

Jamieson Wellness is dedicated to Inspiring Better Lives Every Day with its portfolio of innovative natural health brands. Established in 1922, the Jamieson brand is Canada's #1 vitamins, minerals and supplements ("VMS") brand. The Company's youtheory brand, acquired in 2022, is an established and growing lifestyle brand in the U.S. Combined, these global brands are available in more than 50 countries worldwide. The Company also offers a variety of innovative VMS products as well as sports nutrition products to consumers in Canada with its Progressive, Smart Solutions, Iron Vegan and Precision brands. The Company is a participant of the United Nations Global Compact and adheres to its principles-based approach to responsible business. For more information please visit www.jamiesonwellness.com .

Investor Relations and Media Contact Information:
Jamieson Wellness
Ruth Winker
416-960-0052
rwinker@jamiesonlabs.com

News Provided by Business Wire via QuoteMedia

JWEL:CA
The Conversation (0)
BriaCell Engages Consulting and Branding Firms to Support Commercial and Market Access Evaluation of Bria-IMT

BriaCell Engages Consulting and Branding Firms to Support Commercial and Market Access Evaluation of Bria-IMT

Charles River Associates (CRA) to evaluate epidemiology, pricing, prescriber dynamics, and market access potential for Bria-IMT in metastatic breast cancer in the USKaleio to support brand strategies and customized commercial-readiness solutionsBria-IMT is currently being evaluated in... Keep Reading...
Syringes with measurement markings overlaid with a fluctuating blue and white line graph.

Zymeworks Expands into Respiratory Market with Theravance Buyout

Oncology-focused drugmaker Zymeworks (NASDAQ:ZYME) has agreed to acquire Theravance Biopharma (NASDAQ:TBPH) for US$929 million in cash, expanding its portfolio into the respiratory segment.The acquisition delivers Zymeworks a 35 percent US net profit share in Yupelri, the first and only... Keep Reading...
Rows of multicolored test tubes with brown, purple, blue and green caps arranged neatly on a white rack.

Merck KGaA to Acquire Bio-Techne in US$11.3 Billion Deal

Merck KGaA (ETR:MRK,OTCPL:MKGAF) has agreed to acquire life sciences supplier Bio-Techne (NASDAQ:TECH) for US$11.3 billion in cash, marking the firm’s largest transaction in a decade.Under a definitive agreement announced on Thursday (June 25), Merck KGaA will pay US$73 per share, representing a... Keep Reading...
BriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT

BriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT

Agreement supports potential commercial readiness for Bria-IMT using Uneedle's proprietary microneedle technology for intradermal administration Technology is currently used in BriaCell's pivotal Phase 3 study and is designed to support faster, more convenient administration while enhancing the... Keep Reading...
Blank pill bottle spilling a variety of pharmaceutical pills and capsules.

5 Biggest Pharmaceutical ETFs for Investors in 2026

Experienced and novice investors alike may want to consider pharmaceutical exchange-traded funds (ETFs) as a way to gain exposure to the top pharma companies and the pharma market as a whole. Like all ETFs, pharmaceutical ETFs are a good option for those who want to trade a set of assets in the... Keep Reading...
InMed Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update

InMed Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update

InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today reports financial results for the third quarter of the fiscal year 2026... Keep Reading...

Interactive Chart

Latest Press Releases

Related News